Trial Profile
Open-label, Multi Center Study for an Evaluation of Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability of the 18F-labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY94-9392 Following a Single Intravenous Administration of 300 MBq (Corresponding to ≤ 100 µg Total Quantity) in Healthy Volunteers, as Well as the Investigation of Safety, Tolerability, Pharmacokinetics, and Diagnostic Performance of the Tracer in PET/CT in Cancer Patients or Patients With Inflammation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jul 2019
Price :
$35
*
At a glance
- Drugs BAY 949392 (Primary)
- Indications Adenocarcinoma; Breast cancer; Cancer; Inflammation; Non-small cell lung cancer; Prostate cancer
- Focus Diagnostic use
- Sponsors Life Molecular Imaging
- 24 Apr 2014 New trial record